On Tuesday, Viridian Therapeutics Inc (NASDAQ: VRDN) opened higher 3.78% from the last session, before settling in for the closing price of $22.75. Price fluctuations for VRDN have ranged from $10.93 to $24.18 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -12.71% over the past five years. Company’s average yearly earnings per share was noted 27.08% at the time writing. With a float of $66.40 million, this company’s outstanding shares have now reached $76.36 million.
Let’s look at the performance matrix of the company that is accounted for 96 employees.
Viridian Therapeutics Inc (VRDN) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Viridian Therapeutics Inc is 13.04%, while institutional ownership is 82.45%. The most recent insider transaction that took place on Sep 27 ’24, was worth 117,050. In this transaction Chief Operating Officer of this company bought 5,000 shares at a rate of $23.41, taking the stock ownership to the 6,000 shares. Before that another transaction happened on Sep 27 ’24, when Company’s President and CEO bought 21,400 for $23.33, making the entire transaction worth $499,262. This insider now owns 21,400 shares in total.
Viridian Therapeutics Inc (VRDN) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -1.09 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -1.27) by 0.18. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 27.08% per share during the next fiscal year.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
Check out the current performance indicators for Viridian Therapeutics Inc (VRDN). In the past quarter, the stock posted a quick ratio of 15.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6216.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.25, a number that is poised to hit -1.06 in the next quarter and is forecasted to reach -4.18 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Viridian Therapeutics Inc (NASDAQ: VRDN) saw its 5-day average volume 1.49 million, a positive change from its year-to-date volume of 1.15 million. As of the previous 9 days, the stock’s Stochastic %D was 78.10%. Additionally, its Average True Range was 1.52.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 92.57%, which indicates a significant increase from 80.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.39% in the past 14 days, which was lower than the 73.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.33, while its 200-day Moving Average is $16.80. Nevertheless, the first resistance level for the watch stands at $24.60 in the near term. At $25.58, the stock is likely to face the second major resistance level. The third major resistance level sits at $26.57. If the price goes on to break the first support level at $22.62, it is likely to go to the next support level at $21.63. Assuming the price breaks the second support level, the third support level stands at $20.65.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
There are currently 63,822K shares outstanding in the company with a market cap of 1.80 billion. Presently, the company’s annual sales total 310 K according to its annual income of -237,730 K. Last quarter, the company’s sales amounted to 70 K and its income totaled -64,990 K.
